Ozempic May Curb Alcoholism: New Study Shows Promising Results 2026

Ozempic, the drug famous for treating type 2 diabetes and aiding weight loss, may also help reduce alcohol consumption in people with alcohol use disorder, according to a new study published in The Lancet. The findings offer fresh hope for addiction treatment and suggest that the drug's effects extend far beyond blood sugar and weight control.

What the Study Found

The study, published earlier this month in The Lancet, is the first large-scale randomized controlled trial to investigate the effects of semaglutide—the active ingredient in Ozempic—on alcohol use disorder. Researchers followed 108 adults with both obesity and alcohol use disorder for 26 weeks.

Participants were divided into two groups: one received weekly semaglutide injections, while the other received a placebo. The results were striking: those taking semaglutide experienced a 41% reduction in heavy drinking days, compared to a 26% reduction in the placebo group.

This is a significant milestone because previous evidence on using these drugs for addiction was based only on small studies or anecdotal reports. Now, with a rigorously designed trial, scientists have a clearer picture of the potential benefits.

Why It Matters

Alcohol use disorder affects millions of people worldwide and can lead to serious health problems, including liver disease, heart disease, and mental health issues. Current treatments include behavioral therapy and medications, but relapse rates remain high.

If semaglutide can help reduce heavy drinking, it could become a valuable new tool in the fight against addiction. Moreover, because Ozempic is already approved for diabetes and obesity, doctors might be able to prescribe it off-label for alcohol use disorder relatively quickly, pending further research.

However, experts caution that more studies are needed to confirm these findings and to understand the long-term effects and safety profile of semaglutide in this context.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist, meaning it mimics a hormone that regulates appetite and blood sugar. It slows digestion and increases feelings of fullness, which is why it's effective for weight loss.

But GLP-1 receptors are also found in the brain's reward system, which plays a key role in addiction. It's thought that semaglutide may reduce the rewarding effects of alcohol, making it less appealing and helping people cut back.

This mechanism is not yet fully understood, but the new study adds weight to the idea that GLP-1 agonists could be repurposed for addiction treatment.

Key Takeaways from the Study

• Significant reduction: Semaglutide cut heavy drinking days by 41% versus 26% with placebo.
• Large trial: 108 adults with obesity and alcohol use disorder participated over 26 weeks.
• First of its kind: This is the first large randomized controlled trial of its kind.
• Potential new treatment: If confirmed, semaglutide could become a new option for alcohol use disorder.
• Need for more research: Longer and larger studies are needed to confirm benefits and safety.

Comparing Semaglutide to Other Treatments

To put these results in context, here's how semaglutide compares to existing treatments for alcohol use disorder:

While direct comparisons are difficult due to different study designs, semaglutide's effect size appears promising and comparable to or better than some existing options.

What to Watch Next

The researchers are calling for larger and longer trials to confirm these findings and to test semaglutide in people with alcohol use disorder who do not have obesity. They also want to investigate whether the drug can help with other addictive behaviors, such as smoking or gambling. The background to this story is set out in Ozempic Weight Loss Linked to Less Exercise, Study Finds. A related thread runs through Ozempic Reshapes Eating Habits as Ultra-Processed Foods Cash. Earlier coverage in Ozempic Disrupts Wedding Dress Industry: New Fit Challenges shows how the argument developed.

In the meantime, patients should not self-medicate with Ozempic for alcohol problems. It is a prescription drug with potential side effects, including nausea, vomiting, and risk of pancreatitis. Anyone struggling with alcohol use should consult a healthcare provider. A closer look at the same subject appears in Ozempic Disrupts Wedding Dress Industry with Dramatic Weight Loss. Anyone following the wider picture can start with Alcoholism at 16: How I Got 6 Months to Live by 26. The same theme surfaces in Ozempic and Mounjaro Linked to Rare Eye Disorder, Australian, which takes a different angle.

As the science evolves, Ozempic and similar drugs could transform how we treat addiction—offering a new path for those who have not found relief with existing therapies. Context on how this played out before sits in Instagram Addiction and Alcoholism Share Common Ground. A companion piece, Phil Collins Alcoholism: Life-Threatening Battle and Recovery, approaches the same subject from another angle.